Company code: Jiangsu Kanion Pharmaceutical Co.Ltd(600557) company abbreviation: Jiangsu Kanion Pharmaceutical Co.Ltd(600557) Jiangsu Kanion Pharmaceutical Co.Ltd(600557)
Annual report for 2021
March 2022
Important tips
1、 The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and completeness of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 2、 All directors of the company attended the board meeting. 3、 Lixin Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 4、 Xiao Wei, the person in charge of the company, Xiao Anliang, the person in charge of accounting, and Xiao Anliang, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in the annual report. 5、 The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period approved by the resolution of the board of directors
Audited by Lixin Certified Public Accountants (special general partnership), as of December 31, 2021, the company’s profit available for distribution at the end of the period was 340888232546 yuan.
From February 19, 2021 to July 30, 2021, the company completed the share repurchase, and the total amount of funds used was 17999915188 yuan (including transaction costs). According to the provisions of the rules on share repurchase of listed companies, it is regarded as cash dividend.
In combination with the above situation, from the perspective of the actual operation of the company, the board of directors decided that no cash dividends, bonus shares and capital reserve will be transferred to share capital in this year, and the undistributed profits of the company will be used to supplement the working capital of the company. 6、 Risk statement of forward-looking statements √ applicable □ not applicable
If this annual report involves forward-looking statements such as future plans, it may be adjusted accordingly according to the market environment. The plan does not constitute the company’s substantive commitment to investors. Investors are reminded to pay attention to investment risks. 7、 Whether there is any non operational occupation of funds by the controlling shareholders and their related parties? VIII. Whether there is any external guarantee in violation of the specified decision-making procedures? IX. whether more than half of the directors cannot guarantee the authenticity, accuracy and integrity of the annual report disclosed by the company? X. major risk tips
During the reporting period, there were no particularly significant risks that had a material impact on the company’s production and operation. The company has described various possible risks and Countermeasures in detail in this report. Please refer to “(IV) possible risks” of “VI. discussion and analysis of the company on the future development of the company” in “section III Management Discussion and analysis”. 11、 Others □ applicable √ not applicable
catalogue
Section 1 interpretation four
Section II Company Profile and main financial indicators five
Section III Management Discussion and Analysis eight
Section IV corporate governance thirty-six
Section V environmental and social responsibility fifty-one
Section VI important matters fifty-four
Section VII changes in shares and shareholders sixty-two
Section 8 preferred shares seventy
Section IX relevant information of bonds seventy
Section x financial report seventy-one
1、 Financial statements containing the signatures and seals of the person in charge of the company, the person in charge of accounting work and the person in charge of accounting organization (Accounting Supervisor);
Catalogue of documents for future reference II. The original audit report with the seal of the accounting firm and the signature and seal of the certified public accountant;
3、 The originals of all company documents and announcements publicly disclosed on the website designated by the CSRC during the reporting period.
Section I interpretation
1、 Interpretation
In this report, unless the context otherwise requires, the following words have the following meanings:
Interpretation of common words
CSRC refers to the China Securities Regulatory Commission
Exchange means Shanghai Stock Exchange
Jiangsu Kanion Pharmaceutical Co.Ltd(600557) . The public refers to Jiangsu Kanion Pharmaceutical Co.Ltd(600557)
Company, company
Kangyuan group refers to Jiangsu Kangyuan Group Co., Ltd
Kangyuan sunshine refers to Jiangsu Kangyuan sunshine Pharmaceutical Co., Ltd
Kangyuan Judu refers to Jiangxi Kangyuan Judu Pharmaceutical Co., Ltd
Yiweiyuan refers to Jiangsu Lianyungang Port Co.Ltd(601008) yiweiyuan Trading Co., Ltd
“Party construction + n” refers to the company’s working mode of “party construction + market”, “party construction + project” and “party construction + culture”.
Prescription drugs prescribed or approved by the national health administrative department and required to be prescribed by doctors or other medical professionals refer to drugs that can be used under the supervision or guidance of doctors, pharmacists or other medical professionals.
The national catalogue of essential drugs is the basis for medical institutions to allocate and use drugs. The catalogue of basic drugs refers to the drugs in the catalogue that meet the basic medical and health needs, have appropriate dosage forms, reasonable prices, can ensure supply and can be fairly obtained by the public.
The opinions on further ensuring the supply and price of drugs in short supply (gbfjy “986” refers to [2019] No. 47) requires that the proportion of varieties of essential drugs provided by government run grass-roots medical and health institutions, secondary public hospitals and tertiary public hospitals shall not be less than 90% and 80% respectively in principle 60%。
Further work on the requirements of “GJF [2019] No. 47” refers to the shortage of drugs, Promote medical institutions at all levels to form a “1 + X” medication mode dominated by essential drugs (“1” is the national catalogue of essential drugs, “X” is non essential drugs, which shall be determined by all localities according to actual conditions).
The national medical insurance catalogue and the catalogue of medical insurance indexes of national basic medical insurance, industrial injury insurance and maternity insurance are the standards for the payment of drug expenses by the basic medical insurance, industrial injury insurance and maternity insurance funds.
GMP refers to the abbreviation of good manufacturing practice, which is the standard of drug production quality management.
FDA means the U.S. Food and drug administration
Center for drug evaluation (CDE) refers to the technical evaluation institution of drug registration of the State Food and drug administration, which provides technical support for drug registration.
DRG refers to the abbreviation of diagnosis related groups in English, and the relevant score of disease diagnosis
Group.
The regional point method total budget and payment by disease score are a fuzzy mathematical dip method to solve the problem of medical insurance payment, including payment by disease and total budget management.
CMC refers to the abbreviation of chemical manufacturing and control in English, including production process, impurity research, quality research and stability research, that is, pharmaceutical research.
Section II Company Profile and main financial indicators
1、 Company information
Chinese name of the company Jiangsu Kanion Pharmaceutical Co.Ltd(600557)
Chinese abbreviation of the company Jiangsu Kanion Pharmaceutical Co.Ltd(600557)
The foreign language name of the company is Jiangsu Kanion Pharmaceutical Co., Ltd
The abbreviation of the company’s foreign name is Kanion pharmaceutical
Legal representative of the company: Xiao Wei
2、 Contact person and contact information
Secretary of the board of directors and securities affairs representative
Name: Qiu Hongtao, Chen Yanxi
Contact address: Jiangning industrial city, economic and Technological Development Zone, Jiangsu Lianyungang Port Co.Ltd(601008) City, Jiangsu Province
Tel: 051885521990
Fax: 051885521990
E-mail [email protected]. [email protected].
3、 Basic information
Registered address: Jiangning industrial city, economic and Technological Development Zone, Jiangsu Lianyungang Port Co.Ltd(601008) City, Jiangsu Province
Office address: Jiangning industrial city, economic and Technological Development Zone, Jiangsu Lianyungang Port Co.Ltd(601008) City, Jiangsu Province
The postal code of the company’s office address is 222047
Company website: www.kanion.com com.
E-mail [email protected].
4、 Information disclosure and preparation location
The media name and website of the annual report disclosed by the company include China Securities News, Shanghai Securities News, securities daily and securities times
Website of the stock exchange where the company discloses the annual report www.sse com. cn.
The company’s annual report is prepared at the company’s securities affairs department and Shanghai Stock Exchange
5、 Company stock profile
Company stock profile
Stock type stock exchange stock abbreviation stock code
A-share Shanghai Stock Exchange Jiangsu Kanion Pharmaceutical Co.Ltd(600557) Jiangsu Kanion Pharmaceutical Co.Ltd(600557)
6、 Other relevant information
Name of the accounting firm employed by the company: Lixin Certified Public Accountants (special)
